Literature DB >> 17336710

Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an interleukin 1 receptor antagonist.

Brian D Thornton1, Hal M Hoffman, Adarsh Bhat, Burl R Don.   

Abstract

Familial cold autoinflammatory syndrome (FCAS) is an autosomal dominant disorder characterized by episodic fever, arthralgias, conjunctivitis, and rash triggered by cold exposure. FCAS is rarely associated with progressive renal insufficiency caused by renal amyloidosis. The genetic defect in patients with this disorder is caused by a mutation in the gene encoding the protein cryopyrin, leading to uninhibited activation of systemic inflammation through specific cellular signaling with increased production of a number of key cytokines, including interleukin 1. We describe the successful treatment of a patient with renal amyloidosis caused by FCAS by using a novel interleukin 1-receptor antagonist. Use of specific anticytokine therapy may be a new paradigm in the treatment of patients with renal amyloidosis caused by systemic inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17336710     DOI: 10.1053/j.ajkd.2006.10.026

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  12 in total

1.  A case of cryopyrin-associated periodic syndrome with kidney transplant failure.

Authors:  Rie Imaizumi; Yasuo Ishii; Katsuyuki Miki; Shinji Kudo; Toru Murakami; Ichiro Koyama; Ichiro Nakajima; Shohei Fuchinoue; Yasushi Kawaguchi; Atsuo Taniguchi; Satoshi Teraoka
Journal:  CEN Case Rep       Date:  2014-06-14

Review 2.  An expanding role for interleukin-1 blockade from gout to cancer.

Authors:  Charles Anthony Dinarello
Journal:  Mol Med       Date:  2014-12-16       Impact factor: 6.354

Review 3.  Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies.

Authors:  Giulio Cavalli; Charles A Dinarello
Journal:  Rheumatology (Oxford)       Date:  2015-07-23       Impact factor: 7.580

Review 4.  Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses.

Authors:  Raphaela Goldbach-Mansky; Daniel L Kastner
Journal:  J Allergy Clin Immunol       Date:  2009-12       Impact factor: 10.793

Review 5.  Therapy of autoinflammatory syndromes.

Authors:  Hal M Hoffman
Journal:  J Allergy Clin Immunol       Date:  2009-12       Impact factor: 10.793

6.  Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS).

Authors:  Ori Toker; Philip J Hashkes
Journal:  Biologics       Date:  2010-05-25

Review 7.  Of Inflammasomes and Alarmins: IL-1β and IL-1α in Kidney Disease.

Authors:  Hans-Joachim Anders
Journal:  J Am Soc Nephrol       Date:  2016-08-11       Impact factor: 10.121

Review 8.  Treating inflammation by blocking interleukin-1 in humans.

Authors:  Charles A Dinarello; Jos W M van der Meer
Journal:  Semin Immunol       Date:  2013-11-23       Impact factor: 11.130

Review 9.  Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.

Authors:  Charles A Dinarello; Anna Simon; Jos W M van der Meer
Journal:  Nat Rev Drug Discov       Date:  2012-08       Impact factor: 84.694

Review 10.  NOD-like receptors and inflammation.

Authors:  Rebeccah J Mathews; Michael B Sprakes; Michael F McDermott
Journal:  Arthritis Res Ther       Date:  2008-11-25       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.